US Pharma MarketingBIO board spoke with national security, health officials on China, CEO says
BIO makes China political strategy a top priority as US weighs outbound investment limits; CEO Crowley says biotech may fall under COINS Act. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The…
As companies grapple with how to best compete with — or voice concerns over — China’s growing biotech prowess, crafting a political strategy has become one of the top priorities at the trade group BIO, according to ...
Source: Endpoints News